A Study of 177Lu-PSMA-617 in People With Gliomas
- Status
- RECRUITING
- Phase
- PHASE1
Clinical Trials Related to 177Lu-PSMA-617
Related studies linked through entity extraction aliases.
177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer
- Status
- RECRUITING
- Phase
- PHASE1
177Lu-PSMA-617 in Metastatic Castration Resistant Prostate Cancer (mCRPC) With Bone Marrow Involvement and Cytopenia
- Status
- WITHDRAWN
- Phase
- PHASE2
177LuPSMA in Renal Cell Carcinoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Personalized vs. Fixed-Activity 177Lu-PSMA-617 Radiopharmaceutical Therapy (PRODIGY-2)
- Status
- RECRUITING
- Phase
- PHASE1
Radiopharmaceutical Treatment of Advanced Kidney Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Comparison of Changes in Tumor Burden in 68Ga-PSMA-11 PET/CT and 177Lu-PSMA SPECT/CT in Metastatic Castration-resistant Prostate Cancer
- Status
- COMPLETED
- Phase
- N/A
177Lu-PSMA, Niraparib/AA Plus Prednisone for Prostate Cancer
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
LuCarbo - a Study of 177Lu-PSMA-617 Plus Carboplatin in Metastatic Castrate-resistant Prostate Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Cabazitaxel in Combination With 177Lu-PSMA-617 in Metastatic Castration-resistant Prostate Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
EBRT + Lu-PSMA for N1M0 Prostate Cancer
- Status
- COMPLETED
- Phase
- PHASE1
EVOLUTION: 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With mCRPC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study of Stereotactic Body Radiotherapy and 177Lu-PSMA-617 for the Treatment of Prostate Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Phase I Study of 225Ac-J591 Plus 177Lu-PSMA Small Molecule for Progressive Metastatic Castration Resistant Prostate Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
177Lu-PSMA-617 Managed Access Program for mCRPC Patients
- Status
- NO_LONGER_AVAILABLE
- Phase
- N/A
An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Lutetium-177-PSMA-617 in Oligo-metastatic Hormone Sensitive Prostate Cancer
- Status
- COMPLETED
- Phase
- PHASE2